<DOC>
	<DOCNO>NCT02165566</DOCNO>
	<brief_summary>Insulin preparation -random assignment regular insulin lin lispro insulin first treatment- administer constant infusion rate ( 0.04 units/Kg/h ) patient present blood glucose concentration ≥180 mg/dl discontinue blood glucose concentration ≤140 mg/dl ( therapeutic blood glucose concentration drop ) . Further reduction blood glucose concentration discontinuation insulin infusion record ( post-infusional blood glucose concentration drop ) . During study period blood glucose concentration , whole blood , measure every 30 minute . At least 6 hour interval allow 2 treatment .</brief_summary>
	<brief_title>Humalog Humulin Intensive Insulin Therapy Intensive Care Unit</brief_title>
	<detailed_description>Inclusion criterion : Patients older 18 year age receive full nutritional calorie supply present blood glucose concentration ≥180 mg/dl . Exclusion criterion : moribund patient patient enrolled study exclude . Patients type 1 diabetes , patient insulin-dependent diabetes exclude patient glycated hemoglobin ( glycosilated hemoglobin ) &gt; 5.6 % also exclude potential underlying insulin resistance . A randomized crossover design use . Patients receive insulin infusion therapy prospectively enrol randomly assign start treatment either lispro insulin regular insulin dose 0.04 units/Kg/h . After full enteral parenteral nutrition establish , insulin infusion therapy start blood glucose concentration ≥180 mg/dl ( upper blood glucose concentration threshold ) keep constant blood glucose concentration ≤140 mg/dl ( low blood glucose concentration threshold ) . Insulin infusion discontinue blood glucose concentration reach ≤140 mg/dl . Because crossover design study , patient treat lispro insulin regular insulin infusion allow interval least 6 hour 2 treatment . During study period -IIT insulin infusion discontinued- blood glucose concentration measure every 30 minute whole blood ( blood gas analysis ) blood glucose concentration value return within target threshold ( 140-180 mg/dl ) . The primary outcome measure extent `` residual effect '' insulin ( Hlog Hlin ) infusion discontinue . This variable express ratio blood glucose concentration reduction insulin infusion ( begin insulin infusion blood glucose concentration value &gt; 180 mg/dl , first measurement ≤140 mg/dl ) blood glucose concentration reduction insulin infusion discontinue ( first blood glucose concentration value ≤140 mg/dl low blood glucose concentration value record ) . Secondary end point measure : rate blood glucose concentration reduction insulin infusion ( mg/dl/h-1 ) , duration `` residual effect '' ( time elapse insulin infusion discontinuation lowestblood glucose concentration value ) , rate blood glucose concentration increase low blood glucose concentration value first blood glucose concentration value ≥140 mg/dl .</detailed_description>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>critical care patient blood glucose concentration &gt; 180mg/dl insulin dependent diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>intensive insulin therapy</keyword>
	<keyword>critical care patient</keyword>
	<keyword>blood glucose concentration &gt; 180 mg/dl</keyword>
</DOC>